ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

NCT03686124 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

375

Enrollment

INDUSTRY

Sponsor class

Conditions

Refractory Cancer
Recurrent Cancer
Solid Tumor, Adult
Cancer

Interventions

BIOLOGICAL: IMA203 Product
BIOLOGICAL: IMA203 product- flat dose
BIOLOGICAL: IMA203CD8 Product
DRUG: Nivolumab
DEVICE: IMADetect®

Sponsor

Immatics US, Inc.